Is Johnson & Johnson (JNJ) Overvalued?
We dive into why Johnson & Johnson (JNJ) could be considered overvalued on 2026-07-14, based on AAII’s Value Score and Grade.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Commentary & Analysis
What You Need to Know About Johnson & Johnson's Q3 Earnings
Johnson & Johnson's fiscal Q3 earnings report was released on Wednesday, July 15. Let's dive in to see if (JNJ) missed or beat analyst's expectations.Jenna Brashear
Is Johnson & Johnson (JNJ) Overvalued?
We dive into why Johnson & Johnson (JNJ) could be considered overvalued on 2026-07-13, based on AAII’s Value Score and Grade.Rosalio Madrigal
Is Johnson & Johnson (JNJ) Overvalued?
We dive into why Johnson & Johnson (JNJ) could be considered overvalued on 2026-07-10, based on AAII’s Value Score and Grade.Michael Rose
Is Johnson & Johnson (JNJ) Overvalued?
We dive into why Johnson & Johnson (JNJ) could be considered overvalued on 2026-07-09, based on AAII’s Value Score and Grade.Michael Rose
Financial Summary
| Share Statistics | JNJ | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $616,500.3 | $569.9 | 100% |
|
| Shares Out (Mil) | 2,440.1 | 44.8 | 98% |
|
| Institutional Ownership | 99.9% | 84.6% | 96% |
|
| Float (Mil) | 2,405.9 | 45.1 | 96% |
|
| Beta | 0.23 | 0.67 | 14% |
|
| Avg Daily Volume (000s) | 8,402 | 294 | 96% |
|
| Price Change (52-week) |
52.2% | 65.2% | 81% |
|
| Growth | JNJ | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 2.7% | 6.7% | 26% |
|
| Net Income (5yr) | 12.7% | (2.0%) | 59% |
|
| EPS (5yr) | 14.9% | 14.9% | 55 |
|
| Dividends (5yr) | 5.2% | 0.0% | 98% |
|
| Cash Flow (5yr) | (7.7%) | (14.9%) | 59% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 16 | 23 | 23 | |
| Current EPS | $3.010 | $11.648 | $12.832 | |
| Month Ago EPS | $3.024 | $11.573 | $12.729 | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | $3.017 | $11.575 | $12.710 | |
| Year/Year Chg | 32.6% | 5.6% | 29.4% | |
| Financials | JNJ | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $97,929 | $230 | 99% |
|
| Net Income (TTM) (Mil) | $21,037 | ($11) | 100% |
|
| EPS (TTM) | $8.736 | ($0.600) | 93% |
|
| Operating Cash Flow (TTM) (Mil) | $27,608 | ($6) | 99% |
|
| Net Cash Flow (TTM) (Mil) | $1,845 | $4 | 97% |
|
| Long-Term Debt (Q1) (Mil) | $37,344 | $7 | 98% |
|
| Enterprise Value (Q1) (Mil) | $668,178 | $493 | 100% |
|
| Valuation | JNJ | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.25 | 2.89 | 85% |
|
| P/E | 29.7 | 20.6 | 67% |
|
| Dividend Yield | 2.1% | 0.0% | 77% |
|
| PEG (5yr hist) | 2.0 | 1.1 | 67% |
|
| Ratios | JNJ | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 68.1% | 65.9% | 79% |
|
| Net Margin | 21.5% | (0.2%) | 81% |
|
| ROA | 10.7% | (25.5%) | 88% |
|
| ROE | 25.7% | (21.4%) | 85% |
|
| Liabilities to Assets | 57.7% | 35.5% | 51% |
|
| F-Score | 6 | 3 | 69% |
|
Passing Stock Screens
As of 7/30/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Dogs of the Dow Screen
Factors: Yield, Value
Identifying contrarian plays among the Dow Jones industrial stocks.
| Performance Since Inception: | 4.2% |
| +/- S&P 500: | -3.3 |
